patient_id stringlengths 20 22 | cancer_type stringclasses 1
value | histology stringclasses 2
values | stage_at_diagnosis stringclasses 2
values | molecular_profile dict | baseline_clinical dict | disease_burden_at_dx dict | treatment_course dict | survival_outcomes dict | longitudinal_labs listlengths 3 3 |
|---|---|---|---|---|---|---|---|---|---|
ANODE_SYNTH_2025_10201 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 4.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 33
} | {
"age": 48,
"sex": "female",
"bmi": 26.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 4.5,
"metastatic_sites": [
"pleura",
"contralateral lung",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-03-10T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -15,
"peak_response_20wk_change_percent": -42
},
"pfs_months": 11.07
},
"second_line_t... | {
"overall_survival_months": 31.4,
"censored": false
} | [
{
"date": "2025-02-18T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 7.3,
"platelets_k_uL": 192,
"creatinine_mg_dL": 0.65,
"alt_U_L": 37
},
{
"date": "2025-09-06T00:00:00",
"hemoglobin_g_dL": 10.8,
"wbc_k_uL": 5.3,
"platelets_k_uL": 218,
"creatinine_mg_dL": 1.04,
... |
ANODE_SYNTH_2025_10202 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 6.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 1
} | {
"age": 61,
"sex": "female",
"bmi": 31.6,
"smoking_pack_years": 37,
"ecog_performance_status": 1,
"comorbidities": [
"COPD",
"diabetes"
]
} | {
"primary_tumor_size_cm": 8.1,
"metastatic_sites": [
"liver",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2020-05-05T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -34,
"peak_response_20wk_change_percent": -54
},
"pfs_months": 19.75
},
"second_line_... | {
"overall_survival_months": 23.7,
"censored": false
} | [
{
"date": "2020-03-26T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 8.5,
"platelets_k_uL": 420,
"creatinine_mg_dL": 1.05,
"alt_U_L": 42
},
{
"date": "2020-11-01T00:00:00",
"hemoglobin_g_dL": 13.9,
"wbc_k_uL": 8.7,
"platelets_k_uL": 315,
"creatinine_mg_dL": 0.73,
... |
ANODE_SYNTH_2025_10203 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 7.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 25
} | {
"age": 77,
"sex": "male",
"bmi": 20.4,
"smoking_pack_years": 80,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 7.9,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2022-11-07T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -59,
"peak_response_20wk_change_percent": -44
},
"pfs_months": 24.34
... | {
"overall_survival_months": 31.6,
"censored": false
} | [
{
"date": "2022-10-15T00:00:00",
"hemoglobin_g_dL": 14.2,
"wbc_k_uL": 10.6,
"platelets_k_uL": 226,
"creatinine_mg_dL": 1.23,
"alt_U_L": 18
},
{
"date": "2023-05-06T00:00:00",
"hemoglobin_g_dL": 10.7,
"wbc_k_uL": 7.7,
"platelets_k_uL": 245,
"creatinine_mg_dL": 0.97,
... |
ANODE_SYNTH_2025_10204 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 16.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 32
} | {
"age": 71,
"sex": "female",
"bmi": 33.3,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"COPD"
]
} | {
"primary_tumor_size_cm": 6.1,
"metastatic_sites": [
"brain",
"bone",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-09-06T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -59,
"peak_response_20wk_change_percent": -48
},
"pfs_months": 26.25
},
"second_line... | {
"overall_survival_months": 41.4,
"censored": false
} | [
{
"date": "2021-08-05T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 8.4,
"platelets_k_uL": 393,
"creatinine_mg_dL": 1.01,
"alt_U_L": 72
},
{
"date": "2022-03-05T00:00:00",
"hemoglobin_g_dL": 11.8,
"wbc_k_uL": 8.8,
"platelets_k_uL": 157,
"creatinine_mg_dL": 1.19,
... |
ANODE_SYNTH_2025_10205 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 14.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 22
} | {
"age": 52,
"sex": "female",
"bmi": 27.5,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"diabetes"
]
} | {
"primary_tumor_size_cm": 3.7,
"metastatic_sites": [
"brain",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-10-31T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -54,
"peak_response_20wk_change_percent": -72
},
"pfs_months": 12.55
},
"second_line... | {
"overall_survival_months": 22.4,
"censored": true
} | [
{
"date": "2021-09-24T00:00:00",
"hemoglobin_g_dL": 15.2,
"wbc_k_uL": 5.9,
"platelets_k_uL": 214,
"creatinine_mg_dL": 0.88,
"alt_U_L": 72
},
{
"date": "2022-04-29T00:00:00",
"hemoglobin_g_dL": 10.3,
"wbc_k_uL": 4.6,
"platelets_k_uL": 154,
"creatinine_mg_dL": 1.32,
... |
ANODE_SYNTH_2025_10206 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 15,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 33
} | {
"age": 83,
"sex": "female",
"bmi": 33.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 3.1,
"metastatic_sites": [
"brain",
"bone",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-07-17T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -59,
"peak_response_20wk_change_percent": -65
},
"pfs_months": 27.99
},
"second_line... | {
"overall_survival_months": 45.3,
"censored": true
} | [
{
"date": "2020-06-15T00:00:00",
"hemoglobin_g_dL": 15.5,
"wbc_k_uL": 6.4,
"platelets_k_uL": 301,
"creatinine_mg_dL": 0.98,
"alt_U_L": 25
},
{
"date": "2021-01-13T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 6.4,
"platelets_k_uL": 159,
"creatinine_mg_dL": 1.48,
... |
ANODE_SYNTH_2025_10207 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 6.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 28
} | {
"age": 73,
"sex": "male",
"bmi": 35.7,
"smoking_pack_years": 77,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 8.3,
"metastatic_sites": [
"pleura",
"bone",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2022-05-28T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -25,
"peak_response_20wk_change_percent": -48
},
"pfs_months": 33.51
},
"second_line_th... | {
"overall_survival_months": 57.8,
"censored": false
} | [
{
"date": "2022-05-04T00:00:00",
"hemoglobin_g_dL": 14.1,
"wbc_k_uL": 8.5,
"platelets_k_uL": 289,
"creatinine_mg_dL": 1.13,
"alt_U_L": 20
},
{
"date": "2022-11-24T00:00:00",
"hemoglobin_g_dL": 13.2,
"wbc_k_uL": 4.8,
"platelets_k_uL": 214,
"creatinine_mg_dL": 1.04,
... |
ANODE_SYNTH_2025_10208 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 15.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 3
} | {
"age": 66,
"sex": "female",
"bmi": 19.7,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 6.8,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-11-28T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -31,
"peak_response_20wk_change_percent": -33
},
"pfs_months": 26.28
},
"second_line... | {
"overall_survival_months": 33.4,
"censored": false
} | [
{
"date": "2020-11-09T00:00:00",
"hemoglobin_g_dL": 15,
"wbc_k_uL": 6.6,
"platelets_k_uL": 370,
"creatinine_mg_dL": 0.82,
"alt_U_L": 36
},
{
"date": "2021-05-27T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 6.4,
"platelets_k_uL": 199,
"creatinine_mg_dL": 0.99,
"... |
ANODE_SYNTH_2025_10209 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 6.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 35
} | {
"age": 53,
"sex": "male",
"bmi": 25.2,
"smoking_pack_years": 76,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"hypertension"
]
} | {
"primary_tumor_size_cm": 6.2,
"metastatic_sites": [
"bone",
"pleura",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2022-12-13T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -18,
"peak_response_20wk_change_percent": -75
},
"pfs_months": 16.1
},
"second_line_the... | {
"overall_survival_months": 22.7,
"censored": false
} | [
{
"date": "2022-11-14T00:00:00",
"hemoglobin_g_dL": 12.4,
"wbc_k_uL": 7.4,
"platelets_k_uL": 420,
"creatinine_mg_dL": 1.01,
"alt_U_L": 35
},
{
"date": "2023-06-11T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 4.7,
"platelets_k_uL": 166,
"creatinine_mg_dL": 1.58,
... |
ANODE_SYNTH_2025_10210 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 11.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 32
} | {
"age": 70,
"sex": "female",
"bmi": 28.2,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.2,
"metastatic_sites": [
"liver",
"pleura",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-05-04T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -16,
"peak_response_20wk_change_percent": -36
},
"pfs_months": 16.89
},
"second_line... | {
"overall_survival_months": 35,
"censored": true
} | [
{
"date": "2023-04-18T00:00:00",
"hemoglobin_g_dL": 15.3,
"wbc_k_uL": 8.8,
"platelets_k_uL": 384,
"creatinine_mg_dL": 0.94,
"alt_U_L": 55
},
{
"date": "2023-10-31T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 7.9,
"platelets_k_uL": 243,
"creatinine_mg_dL": 1.54,
... |
ANODE_SYNTH_2025_10211 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 8.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 33
} | {
"age": 86,
"sex": "female",
"bmi": 36,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.8,
"metastatic_sites": [
"pleura",
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-03-07T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -32,
"peak_response_20wk_change_percent": -45
},
"pfs_months": 17.18
},
"second_line... | {
"overall_survival_months": 36,
"censored": false
} | [
{
"date": "2023-01-02T00:00:00",
"hemoglobin_g_dL": 14.7,
"wbc_k_uL": 9.1,
"platelets_k_uL": 400,
"creatinine_mg_dL": 1.28,
"alt_U_L": 76
},
{
"date": "2023-09-03T00:00:00",
"hemoglobin_g_dL": 11.1,
"wbc_k_uL": 7.7,
"platelets_k_uL": 163,
"creatinine_mg_dL": 1.19,
... |
ANODE_SYNTH_2025_10212 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 12.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 5
} | {
"age": 84,
"sex": "female",
"bmi": 32,
"smoking_pack_years": 43,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 3.7,
"metastatic_sites": [
"contralateral lung",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2023-09-06T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -32,
"peak_response_20wk_change_percent": -61
},
"pfs_months": 17.18
... | {
"overall_survival_months": 28.3,
"censored": false
} | [
{
"date": "2023-07-02T00:00:00",
"hemoglobin_g_dL": 12.8,
"wbc_k_uL": 10.5,
"platelets_k_uL": 179,
"creatinine_mg_dL": 1.26,
"alt_U_L": 76
},
{
"date": "2024-03-04T00:00:00",
"hemoglobin_g_dL": 10.6,
"wbc_k_uL": 7.4,
"platelets_k_uL": 357,
"creatinine_mg_dL": 1.05,
... |
ANODE_SYNTH_2025_10213 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 14.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 9
} | {
"age": 48,
"sex": "male",
"bmi": 30.9,
"smoking_pack_years": 59,
"ecog_performance_status": 2,
"comorbidities": []
} | {
"primary_tumor_size_cm": 7.9,
"metastatic_sites": [
"bone",
"liver",
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2022-01-15T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -39,
"peak_response_20wk_change_percent": -65
},
"pfs_months": 16.49
},
"second_line_... | {
"overall_survival_months": 22.7,
"censored": true
} | [
{
"date": "2021-11-19T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 4.6,
"platelets_k_uL": 327,
"creatinine_mg_dL": 1.08,
"alt_U_L": 35
},
{
"date": "2022-07-14T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 4.8,
"platelets_k_uL": 238,
"creatinine_mg_dL": 1.43,
... |
ANODE_SYNTH_2025_10214 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 35
} | {
"age": 61,
"sex": "female",
"bmi": 31.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"hypertension"
]
} | {
"primary_tumor_size_cm": 3.4,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-07-22T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -47,
"peak_response_20wk_change_percent": -83
},
"pfs_months": 18.92
},
"second_line... | {
"overall_survival_months": 30.7,
"censored": true
} | [
{
"date": "2021-06-13T00:00:00",
"hemoglobin_g_dL": 12.6,
"wbc_k_uL": 6.7,
"platelets_k_uL": 167,
"creatinine_mg_dL": 1.23,
"alt_U_L": 59
},
{
"date": "2022-01-18T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 8.2,
"platelets_k_uL": 331,
"creatinine_mg_dL": 1.47,
... |
ANODE_SYNTH_2025_10215 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 4.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 33
} | {
"age": 88,
"sex": "female",
"bmi": 35.8,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.6,
"metastatic_sites": [
"pleura",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-02-16T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -33,
"peak_response_20wk_change_percent": -56
},
"pfs_months": 22.31
},
"second_line... | {
"overall_survival_months": 38.4,
"censored": false
} | [
{
"date": "2023-01-12T00:00:00",
"hemoglobin_g_dL": 11.9,
"wbc_k_uL": 8.7,
"platelets_k_uL": 435,
"creatinine_mg_dL": 0.92,
"alt_U_L": 79
},
{
"date": "2023-08-15T00:00:00",
"hemoglobin_g_dL": 13.2,
"wbc_k_uL": 4.3,
"platelets_k_uL": 203,
"creatinine_mg_dL": 1.1,
... |
ANODE_SYNTH_2025_10216 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 15.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 29
} | {
"age": 78,
"sex": "female",
"bmi": 30.9,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 8.2,
"metastatic_sites": [
"pleura",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-09-19T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -21,
"peak_response_20wk_change_percent": -80
},
"pfs_months": 24.9
},
"second_line_th... | {
"overall_survival_months": 39.5,
"censored": false
} | [
{
"date": "2023-08-28T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 6.8,
"platelets_k_uL": 392,
"creatinine_mg_dL": 1.26,
"alt_U_L": 31
},
{
"date": "2024-03-17T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 4.2,
"platelets_k_uL": 128,
"creatinine_mg_dL": 0.75,
... |
ANODE_SYNTH_2025_10217 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 17.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 29
} | {
"age": 82,
"sex": "female",
"bmi": 33.7,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 7,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-05-31T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -58,
"peak_response_20wk_change_percent": -59
},
"pfs_months": 29.04
},
"second_line... | {
"overall_survival_months": 45,
"censored": true
} | [
{
"date": "2022-05-10T00:00:00",
"hemoglobin_g_dL": 14.5,
"wbc_k_uL": 10.5,
"platelets_k_uL": 212,
"creatinine_mg_dL": 0.62,
"alt_U_L": 26
},
{
"date": "2022-11-27T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 5.9,
"platelets_k_uL": 265,
"creatinine_mg_dL": 1.57,
... |
ANODE_SYNTH_2025_10218 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 14.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 5
} | {
"age": 80,
"sex": "female",
"bmi": 34.1,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 7.8,
"metastatic_sites": [
"brain",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-12-17T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -48,
"peak_response_20wk_change_percent": -57
},
"pfs_months": 28.71
},
"second_line... | {
"overall_survival_months": 43,
"censored": false
} | [
{
"date": "2024-10-09T00:00:00",
"hemoglobin_g_dL": 14.8,
"wbc_k_uL": 10.7,
"platelets_k_uL": 347,
"creatinine_mg_dL": 0.77,
"alt_U_L": 11
},
{
"date": "2025-06-15T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 7.8,
"platelets_k_uL": 240,
"creatinine_mg_dL": 1.19,
... |
ANODE_SYNTH_2025_10219 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 7.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 26
} | {
"age": 58,
"sex": "male",
"bmi": 32.6,
"smoking_pack_years": 62,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"COPD"
]
} | {
"primary_tumor_size_cm": 4.2,
"metastatic_sites": [
"contralateral lung",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2020-06-06T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -50,
"peak_response_20wk_change_percent": -84
},
"pfs_months": 36.96
},
"second_line_th... | {
"overall_survival_months": 67.1,
"censored": true
} | [
{
"date": "2020-04-01T00:00:00",
"hemoglobin_g_dL": 14.3,
"wbc_k_uL": 4.9,
"platelets_k_uL": 325,
"creatinine_mg_dL": 0.61,
"alt_U_L": 33
},
{
"date": "2020-12-03T00:00:00",
"hemoglobin_g_dL": 13.9,
"wbc_k_uL": 7.4,
"platelets_k_uL": 349,
"creatinine_mg_dL": 1.29,
... |
ANODE_SYNTH_2025_10220 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 17.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 8
} | {
"age": 80,
"sex": "female",
"bmi": 22.5,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 6.5,
"metastatic_sites": [
"contralateral lung",
"pleura",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-05-03T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -41,
"peak_response_20wk_change_percent": -37
},
"pfs_months": 13.9
},
"second_line_th... | {
"overall_survival_months": 28.2,
"censored": true
} | [
{
"date": "2020-03-28T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 4.6,
"platelets_k_uL": 222,
"creatinine_mg_dL": 0.85,
"alt_U_L": 10
},
{
"date": "2020-10-30T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 7.4,
"platelets_k_uL": 181,
"creatinine_mg_dL": 1.21,
... |
ANODE_SYNTH_2025_10221 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 7.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 20
} | {
"age": 82,
"sex": "male",
"bmi": 35.5,
"smoking_pack_years": 43,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"diabetes"
]
} | {
"primary_tumor_size_cm": 6.7,
"metastatic_sites": [
"liver",
"contralateral lung",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2023-05-23T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -20,
"peak_response_20wk_change_percent": -39
},
"pfs_months": 44.22
},
"second_line_th... | {
"overall_survival_months": 75.9,
"censored": true
} | [
{
"date": "2023-04-19T00:00:00",
"hemoglobin_g_dL": 15,
"wbc_k_uL": 10.3,
"platelets_k_uL": 285,
"creatinine_mg_dL": 1.14,
"alt_U_L": 13
},
{
"date": "2023-11-19T00:00:00",
"hemoglobin_g_dL": 11.3,
"wbc_k_uL": 5.3,
"platelets_k_uL": 349,
"creatinine_mg_dL": 1.44,
... |
ANODE_SYNTH_2025_10222 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 16.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 17
} | {
"age": 80,
"sex": "female",
"bmi": 19.5,
"smoking_pack_years": 75,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.7,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2022-12-25T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -35,
"peak_response_20wk_change_percent": -47
},
"pfs_months": 24.8
}... | {
"overall_survival_months": 32.5,
"censored": true
} | [
{
"date": "2022-12-04T00:00:00",
"hemoglobin_g_dL": 14.2,
"wbc_k_uL": 7.4,
"platelets_k_uL": 246,
"creatinine_mg_dL": 0.84,
"alt_U_L": 60
},
{
"date": "2023-06-23T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 6.1,
"platelets_k_uL": 170,
"creatinine_mg_dL": 1.59,
... |
ANODE_SYNTH_2025_10223 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 8.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 26
} | {
"age": 65,
"sex": "female",
"bmi": 28.2,
"smoking_pack_years": 48,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 5.1,
"metastatic_sites": [
"bone",
"contralateral lung",
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2021-07-10T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -30,
"peak_response_20wk_change_percent": -43
},
"pfs_months": 41.43
},
"second_line_ther... | {
"overall_survival_months": 70.7,
"censored": false
} | [
{
"date": "2021-05-28T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 9.7,
"platelets_k_uL": 153,
"creatinine_mg_dL": 0.61,
"alt_U_L": 64
},
{
"date": "2022-01-06T00:00:00",
"hemoglobin_g_dL": 12.2,
"wbc_k_uL": 6,
"platelets_k_uL": 186,
"creatinine_mg_dL": 1.34,
"... |
ANODE_SYNTH_2025_10224 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 15.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 18
} | {
"age": 75,
"sex": "female",
"bmi": 26.8,
"smoking_pack_years": 57,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.8,
"metastatic_sites": [
"liver",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2023-12-11T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -15,
"peak_response_20wk_change_percent": -65
},
"pfs_months": 34.53
},
"second_line_th... | {
"overall_survival_months": 55.5,
"censored": true
} | [
{
"date": "2023-11-13T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 11,
"platelets_k_uL": 194,
"creatinine_mg_dL": 1.01,
"alt_U_L": 79
},
{
"date": "2024-06-08T00:00:00",
"hemoglobin_g_dL": 10,
"wbc_k_uL": 5.8,
"platelets_k_uL": 319,
"creatinine_mg_dL": 1.57,
"a... |
ANODE_SYNTH_2025_10225 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 4.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 20
} | {
"age": 56,
"sex": "female",
"bmi": 21.1,
"smoking_pack_years": 37,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.3,
"metastatic_sites": [
"brain",
"bone",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2023-04-29T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -21,
"peak_response_20wk_change_percent": -32
},
"pfs_months": 12.16
... | {
"overall_survival_months": 22.4,
"censored": false
} | [
{
"date": "2023-02-26T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 9.8,
"platelets_k_uL": 441,
"creatinine_mg_dL": 0.85,
"alt_U_L": 78
},
{
"date": "2023-10-26T00:00:00",
"hemoglobin_g_dL": 10.8,
"wbc_k_uL": 8.1,
"platelets_k_uL": 160,
"creatinine_mg_dL": 0.83,
... |
ANODE_SYNTH_2025_10226 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 6.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 6
} | {
"age": 52,
"sex": "female",
"bmi": 20.2,
"smoking_pack_years": 40,
"ecog_performance_status": 2,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 7.8,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2022-12-12T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -20,
"peak_response_20wk_change_percent": -73
},
"pfs_months": 15.61
},
"second_line_... | {
"overall_survival_months": 19.5,
"censored": false
} | [
{
"date": "2022-11-25T00:00:00",
"hemoglobin_g_dL": 14.5,
"wbc_k_uL": 4.8,
"platelets_k_uL": 237,
"creatinine_mg_dL": 1.26,
"alt_U_L": 44
},
{
"date": "2023-06-10T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 4,
"platelets_k_uL": 162,
"creatinine_mg_dL": 1.29,
"... |
ANODE_SYNTH_2025_10227 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 3
} | {
"age": 62,
"sex": "male",
"bmi": 31.3,
"smoking_pack_years": 32,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 7.8,
"metastatic_sites": [
"pleura",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2025-03-12T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -40,
"peak_response_20wk_change_percent": -37
},
"pfs_months": 20.86
... | {
"overall_survival_months": 31.2,
"censored": false
} | [
{
"date": "2025-02-04T00:00:00",
"hemoglobin_g_dL": 14.2,
"wbc_k_uL": 9.3,
"platelets_k_uL": 202,
"creatinine_mg_dL": 0.71,
"alt_U_L": 14
},
{
"date": "2025-09-08T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 8.3,
"platelets_k_uL": 354,
"creatinine_mg_dL": 1.56,
... |
ANODE_SYNTH_2025_10228 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 11.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 17
} | {
"age": 59,
"sex": "male",
"bmi": 27.7,
"smoking_pack_years": 22,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 8.3,
"metastatic_sites": [
"brain",
"contralateral lung",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2024-09-17T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -34,
"peak_response_20wk_change_percent": -39
},
"pfs_months": 29.6
}... | {
"overall_survival_months": 38.3,
"censored": false
} | [
{
"date": "2024-08-02T00:00:00",
"hemoglobin_g_dL": 11.6,
"wbc_k_uL": 5.2,
"platelets_k_uL": 428,
"creatinine_mg_dL": 1.22,
"alt_U_L": 63
},
{
"date": "2025-03-16T00:00:00",
"hemoglobin_g_dL": 11,
"wbc_k_uL": 5.2,
"platelets_k_uL": 296,
"creatinine_mg_dL": 1.45,
"... |
ANODE_SYNTH_2025_10229 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 6.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 30
} | {
"age": 72,
"sex": "female",
"bmi": 34.9,
"smoking_pack_years": 43,
"ecog_performance_status": 1,
"comorbidities": [
"COPD",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 5.1,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2023-05-20T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -57,
"peak_response_20wk_change_percent": -66
},
"pfs_months": 20.24
},... | {
"overall_survival_months": 38.7,
"censored": false
} | [
{
"date": "2023-04-01T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 10.4,
"platelets_k_uL": 298,
"creatinine_mg_dL": 0.6,
"alt_U_L": 29
},
{
"date": "2023-11-16T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 4.6,
"platelets_k_uL": 309,
"creatinine_mg_dL": 1.32,
... |
ANODE_SYNTH_2025_10230 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 4.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 31
} | {
"age": 51,
"sex": "male",
"bmi": 34.5,
"smoking_pack_years": 72,
"ecog_performance_status": 2,
"comorbidities": [
"COPD",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 7.4,
"metastatic_sites": [
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2023-11-25T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -42,
"peak_response_20wk_change_percent": -63
},
"pfs_months": 13.93
},
"second_line_... | {
"overall_survival_months": 19.6,
"censored": false
} | [
{
"date": "2023-10-01T00:00:00",
"hemoglobin_g_dL": 12.6,
"wbc_k_uL": 8.6,
"platelets_k_uL": 415,
"creatinine_mg_dL": 0.96,
"alt_U_L": 20
},
{
"date": "2024-05-23T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 9,
"platelets_k_uL": 219,
"creatinine_mg_dL": 1.01,
"al... |
ANODE_SYNTH_2025_10231 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 15.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 3
} | {
"age": 72,
"sex": "male",
"bmi": 35.1,
"smoking_pack_years": 58,
"ecog_performance_status": 1,
"comorbidities": [
"COPD",
"diabetes"
]
} | {
"primary_tumor_size_cm": 5.1,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2023-06-15T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -10,
"peak_response_20wk_change_percent": -63
},
"pfs_months": 33.94
},
"second_line_th... | {
"overall_survival_months": 55.4,
"censored": true
} | [
{
"date": "2023-05-19T00:00:00",
"hemoglobin_g_dL": 15.3,
"wbc_k_uL": 7.8,
"platelets_k_uL": 344,
"creatinine_mg_dL": 1.05,
"alt_U_L": 56
},
{
"date": "2023-12-12T00:00:00",
"hemoglobin_g_dL": 11.2,
"wbc_k_uL": 7.5,
"platelets_k_uL": 126,
"creatinine_mg_dL": 1.26,
... |
ANODE_SYNTH_2025_10232 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 3.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 20
} | {
"age": 73,
"sex": "female",
"bmi": 33.3,
"smoking_pack_years": 78,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 4.1,
"metastatic_sites": [
"liver",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2025-07-24T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -60,
"peak_response_20wk_change_percent": -36
},
"pfs_months": 16.89
},
"second_line_... | {
"overall_survival_months": 20.8,
"censored": false
} | [
{
"date": "2025-06-25T00:00:00",
"hemoglobin_g_dL": 13.4,
"wbc_k_uL": 9.1,
"platelets_k_uL": 410,
"creatinine_mg_dL": 0.99,
"alt_U_L": 46
},
{
"date": "2026-01-20T00:00:00",
"hemoglobin_g_dL": 11.2,
"wbc_k_uL": 3.9,
"platelets_k_uL": 138,
"creatinine_mg_dL": 1.46,
... |
ANODE_SYNTH_2025_10233 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 35
} | {
"age": 78,
"sex": "female",
"bmi": 36.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.6,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-04-26T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -21,
"peak_response_20wk_change_percent": -51
},
"pfs_months": 27.53
},
"second_line_t... | {
"overall_survival_months": 33.8,
"censored": false
} | [
{
"date": "2023-03-02T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 9.4,
"platelets_k_uL": 365,
"creatinine_mg_dL": 0.73,
"alt_U_L": 55
},
{
"date": "2023-10-23T00:00:00",
"hemoglobin_g_dL": 10.5,
"wbc_k_uL": 8.3,
"platelets_k_uL": 345,
"creatinine_mg_dL": 1.29,
... |
ANODE_SYNTH_2025_10234 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 2.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 3
} | {
"age": 68,
"sex": "female",
"bmi": 24.5,
"smoking_pack_years": 21,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 8.3,
"metastatic_sites": [
"pleura",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2024-04-28T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -37,
"peak_response_20wk_change_percent": -33
},
"pfs_months": 47.31
},
"second_line_th... | {
"overall_survival_months": 76.9,
"censored": false
} | [
{
"date": "2024-03-28T00:00:00",
"hemoglobin_g_dL": 11.9,
"wbc_k_uL": 6.2,
"platelets_k_uL": 377,
"creatinine_mg_dL": 0.8,
"alt_U_L": 20
},
{
"date": "2024-10-25T00:00:00",
"hemoglobin_g_dL": 13.4,
"wbc_k_uL": 8.6,
"platelets_k_uL": 149,
"creatinine_mg_dL": 1.09,
... |
ANODE_SYNTH_2025_10235 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 7.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 1
} | {
"age": 60,
"sex": "female",
"bmi": 27.4,
"smoking_pack_years": 62,
"ecog_performance_status": 1,
"comorbidities": [
"COPD",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 4.8,
"metastatic_sites": [
"bone",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2025-12-12T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -41,
"peak_response_20wk_change_percent": -52
},
"pfs_months": 32.39
},
"second_line_th... | {
"overall_survival_months": 50.8,
"censored": false
} | [
{
"date": "2025-10-13T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 5.1,
"platelets_k_uL": 161,
"creatinine_mg_dL": 1.11,
"alt_U_L": 42
},
{
"date": "2026-06-10T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 8.4,
"platelets_k_uL": 352,
"creatinine_mg_dL": 1.14,
... |
ANODE_SYNTH_2025_10236 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 13
} | {
"age": 48,
"sex": "female",
"bmi": 23.8,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 6.8,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-07-04T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -45,
"peak_response_20wk_change_percent": -42
},
"pfs_months": 19.32
},
"second_line... | {
"overall_survival_months": 38.4,
"censored": false
} | [
{
"date": "2022-04-26T00:00:00",
"hemoglobin_g_dL": 15,
"wbc_k_uL": 5.3,
"platelets_k_uL": 386,
"creatinine_mg_dL": 1.3,
"alt_U_L": 46
},
{
"date": "2022-12-31T00:00:00",
"hemoglobin_g_dL": 11,
"wbc_k_uL": 3.9,
"platelets_k_uL": 225,
"creatinine_mg_dL": 1.07,
"alt... |
ANODE_SYNTH_2025_10237 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 11.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 32
} | {
"age": 72,
"sex": "female",
"bmi": 33.1,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 3.8,
"metastatic_sites": [
"contralateral lung",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-03-11T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -14,
"peak_response_20wk_change_percent": -45
},
"pfs_months": 25.23
},
"second_line_t... | {
"overall_survival_months": 44.5,
"censored": false
} | [
{
"date": "2022-02-18T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 6.9,
"platelets_k_uL": 296,
"creatinine_mg_dL": 0.78,
"alt_U_L": 27
},
{
"date": "2022-09-07T00:00:00",
"hemoglobin_g_dL": 13.9,
"wbc_k_uL": 8.1,
"platelets_k_uL": 161,
"creatinine_mg_dL": 1.14,
... |
ANODE_SYNTH_2025_10238 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 15.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 32
} | {
"age": 87,
"sex": "female",
"bmi": 28.1,
"smoking_pack_years": 46,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"COPD"
]
} | {
"primary_tumor_size_cm": 3.8,
"metastatic_sites": [
"liver",
"pleura",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2021-01-19T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -12,
"peak_response_20wk_change_percent": -79
},
"pfs_months": 15.97
},
"second_line_... | {
"overall_survival_months": 19.9,
"censored": true
} | [
{
"date": "2020-11-17T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 9.7,
"platelets_k_uL": 238,
"creatinine_mg_dL": 0.84,
"alt_U_L": 46
},
{
"date": "2021-07-18T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 6.1,
"platelets_k_uL": 358,
"creatinine_mg_dL": 1.46,
... |
ANODE_SYNTH_2025_10239 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 14.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 0
} | {
"age": 87,
"sex": "female",
"bmi": 25.8,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"COPD"
]
} | {
"primary_tumor_size_cm": 4.7,
"metastatic_sites": [
"brain",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-03-18T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -49,
"peak_response_20wk_change_percent": -62
},
"pfs_months": 27.53
},
"second_line_t... | {
"overall_survival_months": 35.5,
"censored": true
} | [
{
"date": "2024-01-19T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 7.3,
"platelets_k_uL": 410,
"creatinine_mg_dL": 0.78,
"alt_U_L": 79
},
{
"date": "2024-09-14T00:00:00",
"hemoglobin_g_dL": 13.9,
"wbc_k_uL": 4.6,
"platelets_k_uL": 124,
"creatinine_mg_dL": 1.6,
... |
ANODE_SYNTH_2025_10240 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 7.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 8
} | {
"age": 87,
"sex": "female",
"bmi": 35.9,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 4.3,
"metastatic_sites": [
"bone",
"pleura",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-01-24T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -32,
"peak_response_20wk_change_percent": -69
},
"pfs_months": 20.17
},
"second_line... | {
"overall_survival_months": 34.6,
"censored": true
} | [
{
"date": "2020-12-22T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 7.8,
"platelets_k_uL": 256,
"creatinine_mg_dL": 0.91,
"alt_U_L": 61
},
{
"date": "2021-07-23T00:00:00",
"hemoglobin_g_dL": 10.2,
"wbc_k_uL": 6.4,
"platelets_k_uL": 290,
"creatinine_mg_dL": 1.37,
... |
ANODE_SYNTH_2025_10241 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 12.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 33
} | {
"age": 61,
"sex": "female",
"bmi": 24.9,
"smoking_pack_years": 51,
"ecog_performance_status": 2,
"comorbidities": [
"hypertension",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 4.3,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2020-09-16T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -24,
"peak_response_20wk_change_percent": -79
},
"pfs_months": 26.22
},... | {
"overall_survival_months": 44.5,
"censored": false
} | [
{
"date": "2020-07-17T00:00:00",
"hemoglobin_g_dL": 15.1,
"wbc_k_uL": 7.7,
"platelets_k_uL": 270,
"creatinine_mg_dL": 1.15,
"alt_U_L": 60
},
{
"date": "2021-03-15T00:00:00",
"hemoglobin_g_dL": 11.8,
"wbc_k_uL": 5.8,
"platelets_k_uL": 270,
"creatinine_mg_dL": 1.31,
... |
ANODE_SYNTH_2025_10242 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 25
} | {
"age": 88,
"sex": "female",
"bmi": 30.7,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"COPD"
]
} | {
"primary_tumor_size_cm": 7.9,
"metastatic_sites": [
"liver",
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-10-13T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -26,
"peak_response_20wk_change_percent": -82
},
"pfs_months": 17.68
},
"second_line... | {
"overall_survival_months": 32.5,
"censored": false
} | [
{
"date": "2025-08-22T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 4.8,
"platelets_k_uL": 449,
"creatinine_mg_dL": 0.64,
"alt_U_L": 60
},
{
"date": "2026-04-11T00:00:00",
"hemoglobin_g_dL": 10.8,
"wbc_k_uL": 4.8,
"platelets_k_uL": 154,
"creatinine_mg_dL": 1.05,
... |
ANODE_SYNTH_2025_10243 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 2.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 13
} | {
"age": 66,
"sex": "female",
"bmi": 22,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"COPD",
"diabetes"
]
} | {
"primary_tumor_size_cm": 7.3,
"metastatic_sites": [
"pleura",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-09-21T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -37,
"peak_response_20wk_change_percent": -62
},
"pfs_months": 20.9
},
"second_line_th... | {
"overall_survival_months": 42.5,
"censored": false
} | [
{
"date": "2024-09-01T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 10.3,
"platelets_k_uL": 319,
"creatinine_mg_dL": 0.8,
"alt_U_L": 51
},
{
"date": "2025-03-20T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 5.2,
"platelets_k_uL": 306,
"creatinine_mg_dL": 1.3,
... |
ANODE_SYNTH_2025_10244 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 6.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 7
} | {
"age": 79,
"sex": "female",
"bmi": 37,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.3,
"metastatic_sites": [
"brain",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-11-18T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -60,
"peak_response_20wk_change_percent": -81
},
"pfs_months": 15.28
},
"second_line_t... | {
"overall_survival_months": 37.4,
"censored": true
} | [
{
"date": "2021-09-15T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 10.4,
"platelets_k_uL": 249,
"creatinine_mg_dL": 0.7,
"alt_U_L": 60
},
{
"date": "2022-05-17T00:00:00",
"hemoglobin_g_dL": 12.8,
"wbc_k_uL": 8.8,
"platelets_k_uL": 243,
"creatinine_mg_dL": 1.35,
... |
ANODE_SYNTH_2025_10245 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 12.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 19
} | {
"age": 49,
"sex": "male",
"bmi": 29.4,
"smoking_pack_years": 61,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.8,
"metastatic_sites": [
"brain",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2024-06-07T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -49,
"peak_response_20wk_change_percent": -73
},
"pfs_months": 14.59
... | {
"overall_survival_months": 25.1,
"censored": false
} | [
{
"date": "2024-05-08T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 8.3,
"platelets_k_uL": 411,
"creatinine_mg_dL": 1.2,
"alt_U_L": 20
},
{
"date": "2024-12-04T00:00:00",
"hemoglobin_g_dL": 10.2,
"wbc_k_uL": 7.7,
"platelets_k_uL": 380,
"creatinine_mg_dL": 0.7,
"... |
ANODE_SYNTH_2025_10246 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 2.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 14
} | {
"age": 49,
"sex": "female",
"bmi": 26.2,
"smoking_pack_years": 62,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 6.3,
"metastatic_sites": [
"pleura",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2024-12-18T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -60,
"peak_response_20wk_change_percent": -36
},
"pfs_months": 16.92
},
"second_line_... | {
"overall_survival_months": 33.1,
"censored": false
} | [
{
"date": "2024-11-07T00:00:00",
"hemoglobin_g_dL": 15.2,
"wbc_k_uL": 9.4,
"platelets_k_uL": 321,
"creatinine_mg_dL": 0.77,
"alt_U_L": 71
},
{
"date": "2025-06-16T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 7.1,
"platelets_k_uL": 248,
"creatinine_mg_dL": 1.29,
... |
ANODE_SYNTH_2025_10247 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 3.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 7
} | {
"age": 51,
"sex": "male",
"bmi": 32.6,
"smoking_pack_years": 70,
"ecog_performance_status": 1,
"comorbidities": [
"COPD",
"diabetes"
]
} | {
"primary_tumor_size_cm": 6.4,
"metastatic_sites": [
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2023-05-04T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -32,
"peak_response_20wk_change_percent": -72
},
"pfs_months": 27.01
},... | {
"overall_survival_months": 39.4,
"censored": false
} | [
{
"date": "2023-03-07T00:00:00",
"hemoglobin_g_dL": 14.4,
"wbc_k_uL": 6.2,
"platelets_k_uL": 379,
"creatinine_mg_dL": 1.06,
"alt_U_L": 51
},
{
"date": "2023-10-31T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 6.2,
"platelets_k_uL": 277,
"creatinine_mg_dL": 1.08,
... |
ANODE_SYNTH_2025_10248 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 31
} | {
"age": 48,
"sex": "female",
"bmi": 26,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": [
"COPD",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 7.5,
"metastatic_sites": [
"bone",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-09-07T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -35,
"peak_response_20wk_change_percent": -41
},
"pfs_months": 19.52
},
"second_line... | {
"overall_survival_months": 34.6,
"censored": false
} | [
{
"date": "2025-08-21T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 5,
"platelets_k_uL": 194,
"creatinine_mg_dL": 0.66,
"alt_U_L": 29
},
{
"date": "2026-03-06T00:00:00",
"hemoglobin_g_dL": 10.9,
"wbc_k_uL": 8,
"platelets_k_uL": 194,
"creatinine_mg_dL": 1.14,
"alt_... |
ANODE_SYNTH_2025_10249 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 4
} | {
"age": 67,
"sex": "female",
"bmi": 34.1,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 3.8,
"metastatic_sites": [
"brain",
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-03-23T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -53,
"peak_response_20wk_change_percent": -57
},
"pfs_months": 26.48
},
"second_line... | {
"overall_survival_months": 33.4,
"censored": true
} | [
{
"date": "2022-02-17T00:00:00",
"hemoglobin_g_dL": 15.2,
"wbc_k_uL": 4.5,
"platelets_k_uL": 314,
"creatinine_mg_dL": 0.67,
"alt_U_L": 58
},
{
"date": "2022-09-19T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 5.1,
"platelets_k_uL": 230,
"creatinine_mg_dL": 0.79,
... |
ANODE_SYNTH_2025_10250 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 6.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 4
} | {
"age": 54,
"sex": "female",
"bmi": 21.9,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.5,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-04-22T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -58,
"peak_response_20wk_change_percent": -36
},
"pfs_months": 22.08
},
"second_line... | {
"overall_survival_months": 37.7,
"censored": false
} | [
{
"date": "2023-03-27T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 11,
"platelets_k_uL": 213,
"creatinine_mg_dL": 1.15,
"alt_U_L": 53
},
{
"date": "2023-10-19T00:00:00",
"hemoglobin_g_dL": 10.5,
"wbc_k_uL": 6.5,
"platelets_k_uL": 194,
"creatinine_mg_dL": 0.88,
... |
ANODE_SYNTH_2025_10251 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 3.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 31
} | {
"age": 60,
"sex": "male",
"bmi": 27,
"smoking_pack_years": 24,
"ecog_performance_status": 0,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 8.2,
"metastatic_sites": [
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2020-04-03T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -43,
"peak_response_20wk_change_percent": -58
},
"pfs_months": 15.11
},
"second_line_... | {
"overall_survival_months": 25.3,
"censored": true
} | [
{
"date": "2020-03-02T00:00:00",
"hemoglobin_g_dL": 14.3,
"wbc_k_uL": 8,
"platelets_k_uL": 434,
"creatinine_mg_dL": 0.6,
"alt_U_L": 34
},
{
"date": "2020-09-30T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 5.4,
"platelets_k_uL": 176,
"creatinine_mg_dL": 1.57,
"alt... |
ANODE_SYNTH_2025_10252 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 10.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 29
} | {
"age": 82,
"sex": "female",
"bmi": 38,
"smoking_pack_years": 74,
"ecog_performance_status": 0,
"comorbidities": [
"COPD",
"hypertension"
]
} | {
"primary_tumor_size_cm": 3.5,
"metastatic_sites": [
"contralateral lung",
"brain",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2022-09-20T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -11,
"peak_response_20wk_change_percent": -75
},
"pfs_months": 11.4
},
"second_line_t... | {
"overall_survival_months": 19.3,
"censored": false
} | [
{
"date": "2022-07-15T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 10.9,
"platelets_k_uL": 162,
"creatinine_mg_dL": 0.93,
"alt_U_L": 78
},
{
"date": "2023-03-19T00:00:00",
"hemoglobin_g_dL": 10.4,
"wbc_k_uL": 8.5,
"platelets_k_uL": 325,
"creatinine_mg_dL": 1.16,
... |
ANODE_SYNTH_2025_10253 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 12
} | {
"age": 80,
"sex": "female",
"bmi": 37,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"diabetes"
]
} | {
"primary_tumor_size_cm": 5.7,
"metastatic_sites": [
"liver",
"brain",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-11-20T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -23,
"peak_response_20wk_change_percent": -79
},
"pfs_months": 22.31
},
"second_line... | {
"overall_survival_months": 32.8,
"censored": true
} | [
{
"date": "2024-09-25T00:00:00",
"hemoglobin_g_dL": 15.2,
"wbc_k_uL": 9.7,
"platelets_k_uL": 255,
"creatinine_mg_dL": 1.14,
"alt_U_L": 70
},
{
"date": "2025-05-19T00:00:00",
"hemoglobin_g_dL": 10,
"wbc_k_uL": 7.4,
"platelets_k_uL": 210,
"creatinine_mg_dL": 0.76,
"... |
ANODE_SYNTH_2025_10254 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 16.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15
} | {
"age": 81,
"sex": "female",
"bmi": 37.2,
"smoking_pack_years": 30,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.1,
"metastatic_sites": [
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2025-04-24T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -44,
"peak_response_20wk_change_percent": -44
},
"pfs_months": 30.95
},
"second_line_th... | {
"overall_survival_months": 49.5,
"censored": true
} | [
{
"date": "2025-03-20T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 9.7,
"platelets_k_uL": 269,
"creatinine_mg_dL": 0.7,
"alt_U_L": 70
},
{
"date": "2025-10-21T00:00:00",
"hemoglobin_g_dL": 10.2,
"wbc_k_uL": 5.7,
"platelets_k_uL": 322,
"creatinine_mg_dL": 1.35,
... |
ANODE_SYNTH_2025_10255 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 15.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 0
} | {
"age": 65,
"sex": "male",
"bmi": 33.7,
"smoking_pack_years": 11,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 8.3,
"metastatic_sites": [
"liver",
"pleura",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2023-08-08T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -16,
"peak_response_20wk_change_percent": -30
},
"pfs_months": 15.41
},
"second_line_... | {
"overall_survival_months": 26.9,
"censored": false
} | [
{
"date": "2023-06-10T00:00:00",
"hemoglobin_g_dL": 14.8,
"wbc_k_uL": 7.5,
"platelets_k_uL": 207,
"creatinine_mg_dL": 1.1,
"alt_U_L": 59
},
{
"date": "2024-02-04T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 4.4,
"platelets_k_uL": 333,
"creatinine_mg_dL": 1.51,
... |
ANODE_SYNTH_2025_10256 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 16.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 5
} | {
"age": 69,
"sex": "female",
"bmi": 28.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 8.4,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-08-19T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -51,
"peak_response_20wk_change_percent": -63
},
"pfs_months": 20.5
},
"second_line_... | {
"overall_survival_months": 30.8,
"censored": false
} | [
{
"date": "2022-06-26T00:00:00",
"hemoglobin_g_dL": 13.4,
"wbc_k_uL": 9.6,
"platelets_k_uL": 309,
"creatinine_mg_dL": 0.88,
"alt_U_L": 66
},
{
"date": "2023-02-15T00:00:00",
"hemoglobin_g_dL": 11.3,
"wbc_k_uL": 6.8,
"platelets_k_uL": 350,
"creatinine_mg_dL": 1.25,
... |
ANODE_SYNTH_2025_10257 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 14.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 18
} | {
"age": 61,
"sex": "female",
"bmi": 29,
"smoking_pack_years": 66,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"diabetes"
]
} | {
"primary_tumor_size_cm": 3.1,
"metastatic_sites": [
"pleura",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2023-08-03T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -46,
"peak_response_20wk_change_percent": -65
},
"pfs_months": 20.11
},
"second_line_... | {
"overall_survival_months": 26.2,
"censored": false
} | [
{
"date": "2023-05-25T00:00:00",
"hemoglobin_g_dL": 14.4,
"wbc_k_uL": 10.5,
"platelets_k_uL": 239,
"creatinine_mg_dL": 1.08,
"alt_U_L": 40
},
{
"date": "2024-01-30T00:00:00",
"hemoglobin_g_dL": 11.9,
"wbc_k_uL": 4.6,
"platelets_k_uL": 350,
"creatinine_mg_dL": 1.01,
... |
ANODE_SYNTH_2025_10258 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 13.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 9
} | {
"age": 77,
"sex": "male",
"bmi": 28.1,
"smoking_pack_years": 68,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 4.2,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2021-10-30T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -25,
"peak_response_20wk_change_percent": -73
},
"pfs_months": 2.96
},
"second_line_t... | {
"overall_survival_months": 6.9,
"censored": false
} | [
{
"date": "2021-10-16T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 6.4,
"platelets_k_uL": 350,
"creatinine_mg_dL": 0.63,
"alt_U_L": 14
},
{
"date": "2022-04-28T00:00:00",
"hemoglobin_g_dL": 10.6,
"wbc_k_uL": 8.3,
"platelets_k_uL": 242,
"creatinine_mg_dL": 1.45,
... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.